Spatial access to opioid treatment program and alcohol and cannabis outlets: analysis of missed doses of methadone during the first, second, and third 90 days of treatment

References

• NIH. Overdose death rates: National Institute on Drug Abuse (NIDA); 2018. https://www.drugabuse.gov/related-topics/trends-statistics/overdose-death-rates. [last accessed 15 Dec 2018].
   Google Scholar
• Washington State Department of Health Services Center for Health Statistic. Death data. https://www.doh.wa.gov/DataandStatisticalReports/HealthStatistics/Death. [last accessed 15 Dec 2018].
   Google Scholar
• Washington State Department of Health. Washington State Drug Overdose Quarterly Report. 2017. https://www.doh.wa.gov/DataandStatisticalReports/InjuryViolenceandPoisoning/InjuryData/WashingtonStateInjuryDataTables/OpioidQuarterlyReport.
   Google Scholar
• Nielsen S, Larance B, Lintzeris N. Opioid agonist treatment for patients with dependence on prescription opioids. JAMA. 2017;317:967–68. doi:10.1001/jama.2017.0001.
   PubMed Web of Science ®Google Scholar
• SAMHSA. National Survey of Substance Abuse Treatment Services (N-SSATS): 2016. Data on substance abuse treatment facilities. Data on Substance Abuse Treatment Facilities. BHSIS Series S-93, HHS Publication No. (SMA) 17–5039. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2016. https://wwwdasis.samhsa.gov/dasis2/nssats/2016_nssats_rpt.pdf.
   Google Scholar
• Nosyk B, Anglin MD, Brissette S, Kerr T, Marsh DC, Schackman BR, Wood E, Montaner JS. A call for evidence-based medical treatment of opioid dependence in the United States and Canada. Health Aff (Millwood). 2013;32:1462–69.
   PubMed Web of Science ®Google Scholar
• Sordo L, Barrio G, Bravo MJ, Indave BI, Degenhardt L, Wiessing L, Ferri M, Pastor-Barriuso. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. Bmj. 2017;357. doi:10.1136/bmj.j1550 (Published 26 April 2017).
   Web of Science ®Google Scholar
• Larochelle MR, Bernson D, Land T, Stopka TJ, Wang N, Xuan Z, Bagley SM, Liebschutz JM, Walley AY. Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: A cohort study. Ann Intern Med. 2018;169:137–45.
   PubMed Web of Science ®Google Scholar
• Ma J, Bao YP, Wang RJ, Su MF, Liu MX, Li JQ, Degenhardt L, Farrell M, Blow FC, Ilgen M, et al. Effects of medication-assisted treatment on mortality among opioids users: a systematic review and meta-analysis. Mol Psychiatry. 2018. doi:10.1038/s41380-018-0094-5.
   Web of Science ®Google Scholar
• SAMHSA. Federal guidelines for opioid treatment programs. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2015.
   Google Scholar
• Attorneys, at the Legal Action Center authored. Know Your Rights: Rights for Individuals on Medication-Assisted Treatment. Rockville, MD: Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration. HHS Publication No. (SMA) 09–4449; 2009.
   Google Scholar
• SAMHSA. Opioid drugs in maintenance and detoxification treatment of opiate addiction; proposed modification of dispensing restrictions for buprenorphine and buprenorphine combination as used in approved opioid treatment medications. Final rule. Fed Regist. 2012;77:72752–61.
   PubMedGoogle Scholar
• Nguyen LH, Nguyen HTT, Nguyen HLT, Tran BX, Latkin CA. Adherence to methadone maintenance treatment and associated factors among patients in Vietnamese mountainside areas. Subst Abuse Treat Prev Policy. 2017;12:31. doi:10.1186/s13011-017-0115-4.
   PubMed Web of Science ®Google Scholar
• Tran BX, Nguyen LH, Tran TT, Latkin CA. Social and structural barriers for adherence to methadone maintenance treatment among Vietnamese opioid dependence patients. PLoS One. 2018;13:e0190941. doi:10.1371/journal.pone.0190941.
   PubMed Web of Science ®Google Scholar
• Haskew M, Wolff K, Dunn J, Bearn J. Patterns of adherence to oral methadone: implications for prescribers. J Subst Abuse Treat. 2008;35:109–15. doi:10.1016/j.jsat.2007.08.013.
   PubMed Web of Science ®Google Scholar
• Mattick RP, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2004; Art. No: CD002207. DOI: 10.1002/14651858.CD002207.pub4.
   PubMed Web of Science ®Google Scholar
• Greenwald MK. Heroin craving and drug use in opioid-maintained volunteers: effects of methadone dose variations. Exp Clin Psychopharmacol. 2002;10:39–46.
   PubMed Web of Science ®Google Scholar
• Palmer RS, Murphy MK, Piselli A, Ball SA. Substance abuse treatment drop-out from client and clinician perspectives. Subst Use Misuse. 2009;44:1021–38. doi:10.1080/10826080802495237.
   PubMed Web of Science ®Google Scholar
• Rosenblum A, Cleland CM, Fong C, Kayman DJ, Tempalski B, Parrino M. Distance traveled and cross-state commuting to opioid treatment programs in the United States. J Environ Public Health. 2011;2011:948789. doi:10.1155/2011/948789.
   PubMedGoogle Scholar
• Beardsley K, Wish ED, Fitzelle DB, O’Grady K, Arria AM. Distance traveled to outpatient drug treatment and client retention. J Subst Abuse Treat. 2003;25:279–85.
   PubMed Web of Science ®Google Scholar
• Amiri S, Lutz R, Socías E, McDonell MG, Roll JM, Amram O. Increased distance was associated with lower daily attendance to an opioid treatment program in Spokane County Washington. J Subst Abuse Treat. 2018;93:26–30. doi:10.1016/j.jsat.2018.07.006.
   PubMed Web of Science ®Google Scholar
• Amiri S, Hirchak K, Lutz R, McDonell MG, McPherson SM, Roll JM, Amram O. Three-year retention in methadone opioid agonist treatment: A survival analysis of clients by dose, area deprivation, and availability of alcohol and cannabis outlets. Drug Alcohol Depend. 2018;193:63–68.
   PubMed Web of Science ®Google Scholar
• Zielinski L, Bhatt M, Sanger N, Plater C, Worster A, Varenbut M, Daiter J, Pare G, Marsh DC, Desai D, et al. Association between cannabis use and methadone maintenance treatment outcomes: an investigation into sex differences. Biol Sex Differ. 2017;8:8.
   PubMed Web of Science ®Google Scholar
• Franklyn AM, Eibl JK, Gauthier GJ, Marsh DC. The impact of cannabis use on patients enrolled in opioid agonist therapy in Ontario, Canada. PLoS One. 2017;12:e0187633. doi:10.1371/journal.pone.0187633.
   PubMed Web of Science ®Google Scholar
• Bawor M, Dennis BB, Varenbut M, Daiter J, Marsh DC, Plater C, Worster A, Steiner M, Anglin R, Pare G, et al. Sex differences in substance use, health, and social functioning among opioid users receiving methadone treatment: a multicenter cohort study. Biol Sex Differ. 2015;6:21.
   PubMed Web of Science ®Google Scholar
• Initiative 502. The Washington Marijuana Legalization and Regulation. 2012. .
   Google Scholar
• Tabb LP, Fillmore C, Melly S. Location, location, location: assessing the spatial patterning between marijuana licenses, alcohol outlets and neighborhood characteristics within Washington state. Drug Alcohol Depend. 2018;185:214–18. doi:10.1016/j.drugalcdep.2018.01.004.
   PubMed Web of Science ®Google Scholar
• Peles E, Linzy S, Kreek M, Adelson M. One-year and cumulative retention as predictors of success in methadone maintenance treatment: a comparison of two clinics in the United States and Israel. J Addict Dis. 2008;27:11–25. doi:10.1080/10550880802324382.
   PubMed Web of Science ®Google Scholar
• Peles E, Schreiber S, Adelson M. Factors predicting retention in treatment: 10-year experience of a methadone maintenance treatment (MMT) clinic in Israel. Drug Alcohol Depend. 2006;82:211–17. doi:10.1016/j.drugalcdep.2005.09.004.
   PubMed Web of Science ®Google Scholar
• Washington State Liquor and Cannabis Board. Marijuana license applicants, alcohol off-premises licensees, alcohol on-premises licensees. 2018. https://lcb.wa.gov/records/frequently-requested-lists. [last accessed 15 Jun 2018].
   Google Scholar
• Singh GK. Area deprivation and widening inequalities in US mortality, 1969–1998. Am J Public Health. 2003;93:1137–43.
   PubMed Web of Science ®Google Scholar
• Knighton AJ, Savitz L, Belnap T, Stephenson B, VanDerslice J. Introduction of an area deprivation index measuring patient socioeconomic status in an integrated health system: implications for population health. eGEMs. 2016;4:1238. doi:10.13063/2327-9214.1176.
   PubMedGoogle Scholar
• Hu J, Kind AJH, Nerenz D. Area deprivation index predicts readmission risk at an Urban Teaching Hospital. Am J Med Qual. 2018;33:493–501. doi:10.1177/1062860617753063.
   Web of Science ®Google Scholar
• Kind AJ, Jencks S, Brock J, Yu M, Bartels C, Ehlenbach W, Greenberg C, Smith M. Neighborhood socioeconomic disadvantage and 30-day rehospitalization: a retrospective cohort study. Ann Intern Med. 2014;161:765–74.
   PubMed Web of Science ®Google Scholar
• U.S. Census Bureau. American community survey. American Fact Finder; 2017.
   Google Scholar
• Jones CW, Christman Z, Smith CM, Safferman MR, Salzman M, Baston K, Haroz R. Comparison between buprenorphine provider availability and opioid deaths among US counties. J Subst Abuse Treat. 2018;93:19–25.
   PubMed Web of Science ®Google Scholar
• Salsitz EA, Joseph H, Frank B, Perez J, Richman BL, Salomon N, Kalin MF, Novick DM. Methadone medical maintenance (MMM): treating chronic opioid dependence in private medical practice. A summary report (1983–1998). Mt Sinai J Med. 2000;67:388–97.
   PubMed Web of Science ®Google Scholar
• Matheson C, Thiruvothiyur M, Robertson H, Bond C. Community pharmacy services for people with drug problems over two decades in Scotland: implications for future development. Int J Drug Policy. 2016;27:105–12. doi:10.1016/j.drugpo.2015.11.006.
   PubMed Web of Science ®Google Scholar
• Dooley J, Asbridge M, Fraser J, Kirkland S. Physicians’ attitudes towards office-based delivery of methadone maintenance therapy: results from a cross-sectional survey of Nova Scotia primary-care physicians. Harm Reduct J. 2012;9:20. doi:10.1186/1477-7517-9-20.
   PubMed Web of Science ®Google Scholar
• Shen J, Wang M, Wang X, Zhang G, Guo J, Li X, Li J. Predictors of poor adherence to methadone maintenance treatment in Yunnan Province, China. J Addict Med. 2016;10:40–45.
   PubMed Web of Science ®Google Scholar
• Kelly SM, O’Grady KE, Mitchell SG, Brown BS, Schwartz RP. Predictors of methadone treatment retention from a multi-site study: a survival analysis. Drug Alcohol Depend. 2011;117:170–75. doi:10.1016/j.drugalcdep.2011.01.008.
   PubMed Web of Science ®Google Scholar
• Brady TM, Salvucci S, Sverdlov LS, Male A, Kyeyune H, Sikali E, Desale S, Yu P. Methadone dosage and retention: an examination of the 60 mg/day threshold. J Addict Dis. 2005;24:23–47.
   PubMed Web of Science ®Google Scholar
• Farre M, Mas A, Torrens M, Moreno V, Cami J. Retention rate and illicit opioid use during methadone maintenance interventions: a meta-analysis. Drug Alcohol Depend. 2002;65:283–90.
   PubMed Web of Science ®Google Scholar